Abcam, ab232620, Anti-Mad2L2/REV7 antibody [EPR13657] - BSA and Azide free

Size: 100µg / 1mg
Rabbit Recombinant Monoclonal Mad2L2/REV7 antibody. Carrier free. Suitable for IP, WB, ICC/IF, Flow Cyt (Intra), IHC-P and reacts with Human samples. Cited in 1 publication.
Key facts
Host species:Rabbit,
Clonality:Monoclonal,
Clone number:EPR13657,
Isotype:IgG,
Carrier free:Yes,
Reacts with:Human,
Applications:WB, ICC/IF, Flow Cyt (Intra), IHC-P, IPSee reactivity dataSee the reactivity data table below for information on validated species and application combinations.,
Immunogen:The exact immunogen used to generate this antibody is proprietary information.

Product details:
ab232620 is the carrier-free version of
ab180579
Patented technology
Our RabMAb
technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to
RabMAb® patents
What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:
- High batch-to-batch consistency and reproducibility
- Improved sensitivity and specificity
- Long-term security of supply
- Animal-free batch production
For more information, read more on
recombinant antibodies
Conjugation ready
Our carrier-free antibodies are typically supplied in a PBS-only formulation, purified and free of BSA, sodium azide and glycerol. This conjugation-ready format is designed for use with fluorochromes, metal isotopes, oligonucleotides, and enzymes, which makes them ideal for antibody labelling, functional and cell-based assays, flow-based assays (e.g. mass cytometry) and Multiplex Imaging applications.
Use our
conjugation kits
for antibody conjugates that are ready-to-use in as little as 20 minutes with 1 minute hands-on-time and 100% antibody recovery: available for fluorescent dyes, HRP, biotin and gold.
Compatibility
This product is compatible with the Maxpar
Antibody Labeling Kit from Fluidigm, without the need for antibody preparation. Maxpar
is a trademark of Fluidigm Canada Inc.

Properties and Storage Information:
Form-Liquid, Purification technique-Affinity purification Protein A, Storage buffer-pH: 7.2 - 7.4Constituents: PBS, Shipped at conditions-Blue Ice, Appropriate short-term storage conditions-+4°C, Appropriate long-term storage conditions-+4°C, Storage information-Do Not Freeze

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
The protein Mad2L2 also known as REV7 plays important roles in cellular processes. It has a molecular weight of about 26 kDa and is expressed in various tissues including the testis and placenta. Mad2L2 is an important component of the DNA damage response functioning mainly in the regulation of mitosis and repair of DNA double-strand breaks. It acts as a regulatory subunit and inhibitor of the translesion DNA synthesis (TLS) polymerase complex influencing processes linked to DNA fidelity.
Biological function summary
The protein is important for maintaining genome integrity by participating in the Fanconi anemia (FA) pathway ensuring proper DNA repair. Mad2L2 forms an important part of the homologous recombination repair system and plays a role in the recruitment of additional repair factors. It is often seen as a part of the shieldin complex which works to protect DNA ends during repair. This complex safeguarding allows it to prevent inappropriate activity during the DNA repair process.
Pathways
The involvement of Mad2L2 highlights its critical role in DNA repair mechanisms specifically homologous recombination and non-homologous end joining (NHEJ). It interacts with proteins such as 53BP1 and RIF1 within these pathways to mediate DNA repair. Such interaction is essential for choosing the correct repair pathway based on cellular needs. Mad2L2's function within the pathway guarantees the accurate resolution and repair of DNA lesions.
The protein's relevance underlines its connection to cancer and genetic disorders like Fanconi anemia. Mutations or irregularities in Mad2L2 can contribute to genomic instability leading to cancer development. In particular its interaction with the BRCA1 and BRCA2 proteins is significant; disruptions in these interactions link to increased cancer risk. This connection with tumor suppression pathways makes Mad2L2 an interesting target for therapeutic strategies in oncology.